Head to Head Comparison: Ritter Pharmaceuticals (RTTR) & The Competition
Ritter Pharmaceuticals (NASDAQ: RTTR) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Ritter Pharmaceuticals to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, profitability, earnings and dividends.
Valuation & Earnings
This table compares Ritter Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ritter Pharmaceuticals||N/A||-$18.38 million||-0.30|
|Ritter Pharmaceuticals Competitors||$290.27 million||$35.99 million||59.39|
Institutional and Insider Ownership
33.4% of Ritter Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 28.1% of Ritter Pharmaceuticals shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Ritter Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ritter Pharmaceuticals Competitors||-5,402.73%||-162.16%||-35.93%|
This is a summary of recent ratings and target prices for Ritter Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ritter Pharmaceuticals Competitors||1133||3431||11933||241||2.67|
Ritter Pharmaceuticals presently has a consensus target price of $2.50, indicating a potential upside of 614.29%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.48%. Given Ritter Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Ritter Pharmaceuticals is more favorable than its competitors.
Risk and Volatility
Ritter Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals’ competitors have a beta of 5.81, suggesting that their average stock price is 481% more volatile than the S&P 500.
Ritter Pharmaceuticals competitors beat Ritter Pharmaceuticals on 8 of the 13 factors compared.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.